Photodynamic Therapy (PDT) — Dermatology Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and noncoverage for photodynamic therapy (PDT) in dermatologic indications for Blue Cross Blue Shield - Rhode Island members, including actinic keratoses, certain nonmelanoma skin cancers, and other dermatologic uses.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
inv-01: Medically Necessary Indications
Covered when ALL of the following apply for each indication as specified:
Coverage limited to these indications per Commercial Products section.
inv-02: Not Medically Necessary / Cosmetic Indications
Not covered for the following dermatologic applications:
Evidence insufficient or inconsistent for these uses; may be denied as not medically necessary.
inv-03: Insufficient Evidence / Experimental Uses
Applications with insufficient or inconclusive evidence:
Further randomized controlled trials are needed to establish safety and effectiveness.
Photodynamic therapy (PDT) is not medically necessary for dermatologic applications other than those explicitly listed as medically necessary in this policy. Treatments for indications outside the covered set may be denied because the evidence is insufficient to establish clinically meaningful benefit for those uses.
Examples of dermatologic uses considered not medically necessary include acne vulgaris, high-risk basal cell carcinoma, hidradenitis suppurativa, and mycoses. PDT is also considered not medically necessary when used as a technique for skin rejuvenation, hair removal, or other cosmetic procedures. This determination is based on insufficient or inconsistent evidence and, in some cases, high rates of treatment-related adverse events reported in clinical trials.
Billing and Coding
| 96567 | Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (e.g., lip) by activation of photosensitive drug(s), each phototherapy exposure session. |
| 96573 | Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day. |
| 96574 | Debridement of premalignant hyperkeratotic lesion(s) (ie, targeted curettage, abrasion) followed with photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day. |
| J7308 | Aminolevulinic hydrochloric acid for topical administration, 20%, single unit dosage form (354 mg). |
| J7309 | Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram |
| B36.8-B36.9 | Other superficial mycoses / unspecified superficial mycosis (as listed) |
| B48.8-B49 | Other fungal diseases (codes listed in policy) |
| C44.0-C44.9 | Other and unspecified malignant neoplasm of skin (nonmelanoma skin cancer range) |
| D04.0-D04.9 | Carcinoma in situ of skin (Bowen's disease range) |
| L57.0 | Actinic keratosis |
| L70.0 | Acne vulgaris |
| L73.2 | Hidradenitis suppurativa |
| Q82.5 | Vascular malformations (e.g., port-wine stain) |
Provider Responsibilities and Billing Guidance
Prior Authorization / Benefit Verification
Not applicable. Prior authorization is not required for photodynamic therapy under this policy. However, providers must verify member benefits and coverage prior to treatment as plan benefits may vary.
- Verify member-specific benefits, coverage limits, and medical necessity provisions in the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Coding and Diagnosis Linkage
Use the listed CPT/HCPCS and ICD-10 codes and ensure diagnosis linkage on the claim to a covered indication. Billing with codes that do not correspond to a covered diagnosis may result in claim denial.
Step or Alternative Therapy Considerations
Consider photodynamic therapy (PDT) only for indications where evidence supports effectiveness and after alternative, standard therapies have been considered or are contraindicated. Document prior use or contraindication of first-line treatments when applicable.
- PDT may be considered for nonhyperkeratotic actinic keratoses of the face, scalp, and upper extremities.
- PDT may be considered for low-risk (superficial and nodular) basal cell carcinoma and for cutaneous squamous cell carcinoma in situ only when surgery and radiation are contraindicated.
- When electing PDT instead of surgery or radiotherapy, include documentation of contraindications to surgery/radiation or patient-specific factors that justify PDT as an alternative therapy.
Denial Risk for Non‑Covered Indications
Photodynamic therapy is not medically necessary for many dermatologic and cosmetic applications; claims for non-covered indications are at high risk for denial. Provide clear clinical documentation tying the procedure and codes to an allowed diagnosis and rationale.
- Noncovered/common non-medical indications include acne vulgaris, high-risk basal cell carcinoma, hidradenitis suppurativa, fungal infections (mycoses), skin rejuvenation, hair removal, and other cosmetic uses.
- If treating a non-covered indication, include detailed documentation to demonstrate medical necessity; absence of such documentation may result in denial.
- Refer to the applicable Benefit Booklet or Subscriber Agreement for plan-specific exclusions and member benefit limits.
Background and Rationale
Photodynamic therapy (PDT) uses a topically or systemically applied photosensitizer that is activated by a specific light source to produce reactive intermediates that cause localized tissue injury and necrosis. Randomized controlled trials and systematic reviews support the efficacy of PDT for nonhyperkeratotic actinic keratoses of the face, scalp, and upper extremities; limited RCTs and systematic reviews suggest benefit for certain low-risk basal cell carcinomas and for Bowen disease when surgery or radiation are contraindicated. For several other dermatologic conditions (for example, invasive squamous cell carcinoma, acne, hidradenitis suppurativa, and various noncancerous conditions), the available evidence is limited, inconsistent, or from uncontrolled series, and is insufficient to determine safety and effectiveness.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.